Gunnar M Olsen

This inventor holds 72 USPTO granted patents and 20 published patent applications, plus 6 CIPO patents and 19 EPO patents, primarily in Neurotransmitter Modulators (CPC class A61K). Top assignees: Neurosearch A/s, Abbott Laboratories Corporation. Active years: 1999-2013.

USPTO Granted Patents = 72 (Patent Applications = 20)

% Patents Active = 23.6

CIPO Patents = 6 (Patent Applications = 46)

EPO Patents = 19 (Patent Applications = 17)

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 179(Granted Patents)

Forward Citations (Not Self Cited) = 161(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Copenhagen, DK (1999 - 2000)
Frederiksberg, DK (2002 - 2007)
Frederiksberg, DE (2007)
Smoerum, DK (2007 - 2008)
Ballerup, DK (2002 - 2012)
Smørum, DK (2010 - 2013)
Smorum, DK (2011 - 2013)
Smerum, DK (2013)

Company Filing History:

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 1999-2013

Loading Chart...

Areas of Expertise:

Monoamine Inhibitors

Cholinergic Receptor Modulators

Bicyclic Derivatives

Pyrimidine Derivatives

Oxadiazole Derivatives

Nicotinic Acetylcholine Receptors

Dimeric Compounds

Aryl Derivatives

Pharmaceutical Use

Heteroaryl Derivatives

Enantiomers

Triazole Derivatives

72 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8410271 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2013-04-02),

2. 8372832 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use (2013-02-12),

3. 8343960 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use (2013-01-01),

4. 8263617 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-09-11),

5. 8236793 - Diazabicyclic aryl derivatives as cholinergic receptor modulators (2012-08-07),

6. 8173658 - Diazabicycylic aryl derivatives and their medical use (2012-05-08),

7. 8158619 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use (2012-04-17),

8. 8148365 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use (2012-04-03),

9. 8110588 - 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors (2012-02-07),

10. 8110586 - 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-02-07),

11. 8101598 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use (2012-01-24),

12. 8022081 - Naphthyl substituted azabicyclo derivatives and their use as monomine neurotransmitter re-uptake inhibitors (2011-09-20),

13. 8017631 - Oxadiazole derivatives and their medical use (2011-09-13),

14. 7989470 - 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2011-08-02),

15. 7973082 - Substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors (2011-07-05),

Title: Innovations and Patents of Gunnar M. Olsen

Introduction

Gunnar M. Olsen, based in Smørum, Denmark, is a prominent inventor with a remarkable portfolio of 72 patents. His contributions to pharmacology and neuroscience have positioned him as a significant figure in the research and development of novel therapeutic compounds.

Latest Patents

Among his latest inventions, Gunnar M. Olsen has developed chromen-2-one derivatives designed to act as monoamine neurotransmitter re-uptake inhibitors. This groundbreaking invention not only explores the efficacy of chromen-2-one derivatives but also expands upon their applications in therapeutic methodologies and pharmaceutical compositions. Another noteworthy patent encompasses 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical applications. These novel derivatives serve as cholinergic ligands at the nicotinic acetylcholine receptors and as modulators of monoamine receptors and transporters. The pharmacological profiles of these compounds promise potential treatments for a range of diseases, including disorders related to the central and peripheral nervous systems, inflammation, and neuro-degeneration.

Career Highlights

Throughout his career, Gunnar M. Olsen has collaborated with reputable companies such as Neurosearch A/S and Abbott Laboratories Corporation, demonstrating his commitment to advancing medical science through innovation.

Collaborations

Gunnar has worked alongside notable colleagues, including Dan Peters and Elsebet Østergaard Nielsen. Their collective efforts have contributed to the advancement of new therapeutic solutions, further enhancing the impact of their research and inventions.

Conclusion

Gunnar M. Olsen's extensive patent portfolio and his pioneering work in pharmacology and neuroscience exemplify the spirit of innovation. His inventions not only provide insights into complex biological systems but also hold potential for treating various medical conditions, underscoring the vital role that inventors like him play in advancing healthcare and scientific knowledge.